Scott Byrd, Sudo Biosciences CEO (Frazier Healthcare Partners)

Bris­tol My­ers got the first TYK2 ap­proval. Fra­zier’s new biotech Su­do hopes to get many more

Ear­li­er in Sep­tem­ber, the FDA ap­proved a TYK2 in­hibitor for the first time, a drug from Bris­tol My­ers Squibb for pso­ri­a­sis, with­out slap­ping on the black box safe­ty warn­ing that has cast a shad­ow on the larg­er fam­i­ly of an­ti-in­flam­ma­to­ry drugs it comes from, the JAK in­hibitors.

While Bris­tol My­ers won the first ap­proval, it’s fol­lowed by a suite of oth­ers with TYK2 pro­grams. Now, Fra­zier’s join­ing the fray.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.